Heparin

AHN Invests in State-of-the-art Robotics to Transform Pharmacy Operations

Retrieved on: 
Wednesday, June 29, 2022
Heparin, Neurosurgery, Drexel University College of Medicine, Annual report, Lake Erie College, Patient, Research, Osteopathic medicine in the United States, Pharmacist, XT, Reconciliation (United States Congress), Intelligence, Approximation error, COVID-19, Population, Prescription, Goal, Syringe, National Association Medical Staff Services, Forward-looking statement, Allegheny Health Network, U.S. Securities and Exchange Commission, Automation, Anesthesia, Neurology, United Kingdom, Technology, Private Securities Litigation Reform Act, AHN, Patient safety, Software, Cardiovascular disease, Health, SEC, Risk, Solution, Controlled substance, Physician, IV, Lake Erie College of Osteopathic Medicine, Diabetes, Hospital, Medical device, Risk management, Medicine, Pharmacy, Omnicell

PITTSBURGH,  June 29, 2022 /PRNewswire-PRWeb/ -- Implementing Omnicell's infrastructure of automation, intelligence, and technology-enabled services supports on-site sterile compounding, enhances medication distribution processes, and improves pharmacy supply chain management

Key Points: 
  • Allegheny Health Network (AHN) has invested in state-of-the-art robotic sterile compounding technology from Omnicell, Inc. (Omnicell) that is transforming pharmacy operations at the 14-hospital health care system.
  • According to Laura Mark, vice president of Pharmacy for AHN, the new robots produce IV medications used in critical care areas as well as operating room (OR) syringes.
  • "Compounding the medications in house is more cost effective than outsourcing, it reduces waste, and it allows AHN to mitigate some critical medication shortages," she said.
  • Since 1992, Omnicell has been committed to transforming the pharmacy care delivery model to dramatically improve outcomes and lower costs.

Global Prefilled Syringes Market to 2028 - Collaborations and Investments to Open an Array of Opportunities for the Market to Flourish - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 29, 2022
Pharmaceutical, Health, Medical Devices, Geography, Completeness, Vaccine, Needle, CAGR, Heparin, Syringe, Safety, Glass, Machine taper, Hyaluronic acid, Diluent, Pet, Borosilicate glass

The prefilled syringes global market based on material is segmented into glass based prefilled syringes and polymer based prefilled syringes.

Key Points: 
  • The prefilled syringes global market based on material is segmented into glass based prefilled syringes and polymer based prefilled syringes.
  • The prefilled syringes global market based on design is grouped into single chamber prefilled syringes and dual chamber prefilled syringes.
  • The prefilled syringes global market based on closure system is classified into staked needle prefilled syringes, luer lock prefilled syringes and non-luer lock prefilled syringes.
  • The prefilled syringes global market based on application is categorized into heparin prefilled syringes, vaccines prefilled syringes, therapeutic drugs prefilled syringes, diluents prefilled syringes, surgical application prefilled syringes, hyaluronic acid prefilled syringes and other prefilled syringes applications (other anticoagulant prefilled syringes, saline flush prefilled syringes and contrast imaging agents prefilled syringes).

With Market Size Valued at $337.5 Million by 2026, it's a Healthy Outlook for the Global Antibacterial Glass Market

Retrieved on: 
Tuesday, May 31, 2022
Copper, Hospital, Food, Infection, Time-invariant system, Corning Inc., Pseudomonas fluorescens, Subclinical infection, Health care, National Association Medical Staff Services, Restaurant, Zinc, Syringe, Virus, Glass, Adoption, Tablet, Mark (given name), Tissue, Lists of countries and territories, Forecasting, Housing, Pneumonia, COVID-19, Marketing, Players, Research, Silver, SAN, Bloodstream infections, CAGR, Growth, Fungus, Electronics, Risk, Sodium chloride, Bacteria, Solution, Health, Active ingredient, GIA, AGC Glass Europe, Burn, Awareness, Intensive care unit, Attention, Internet, Fluid mechanics, Decontamination, Patient, Industry, Titanium, Hygiene, Heparin, Technology, Lubricant, Dentistry, School, Food safety, Intelligence, Genetically modified bacteria, Vaccine, Pharmaceutical industry, Others

Companies:41 - Players covered include AGC Glass Europe; Corning Inc.; Essex Safety Glass Ltd.; Glas Trosch Holding AG; Innovative Glass Corporation; Ishizuka Glass Company Limited; Joh.

Key Points: 
  • Companies:41 - Players covered include AGC Glass Europe; Corning Inc.; Essex Safety Glass Ltd.; Glas Trosch Holding AG; Innovative Glass Corporation; Ishizuka Glass Company Limited; Joh.
  • Frequently touched glass surfaces in public transport, schools, public offices, hospital, and others offer abundant growth opportunities for antibacterial glass.
  • The antibacterial glass market is expected to benefit from increasing use of antimicrobial coatings on different types of medical devices.
  • Global Industry Analysts, Inc., ( www.strategyr.com ) is a renowned market research publisher the world`s only influencer driven market research company.

SCAI 2022 Scientific Sessions Highlight Impella Research, Advancements to Improve Cardiogenic Shock Outcomes

Retrieved on: 
Wednesday, May 18, 2022
Medical Devices, Health, General Health, Research, Cardiology, Science, Risk, Cardiomyopathy, International Journal of Cardiology, Sodium bicarbonate, Survival, US Foods, U.S. Securities and Exchange Commission, EDT, Heparin-induced thrombocytopenia, PCI, US FDA, Patient, Multimedia, ABMD, NASDAQ, Decompensation, US, Meta-analysis, Myocardial infarction, Canadian International Council, ASL, Mortality, Heart, Kidney, FDA, U.S. FDA, SCAI, Cardiogenic shock, Bleeding, Heparin, Pulmonary artery, SHOCK, Heart failure, Inferior vena cava, Registry, Lung, Society, Security (finance), PubMed, Cochrane, MD, Pharmaceutical industry, Medical device, Cardiology, Impella, Abiomed

The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).

Key Points: 
  • The patients were divided into two groups those who received Impella support pre-PCI (n=2,970) and those who received Impella support during or post-PCI (n=3,840).
  • The data showed significantly reduced short-term mortality rates in AMICS patients who received Impella support pre-PCI, compared to those who received Impella support during or post-PCI (37.2% vs 53.6%, p=0.002).
  • Details of the presentation and the study abstract are available on the SCAI 2022 Scientific Sessions website .
  • SCAI also provides Abiomed an opportunity to highlight its latest FDA approval, which simplifies Impella management with the goal of improving patient outcomes.

Aura Biosciences Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Retrieved on: 
Tuesday, May 3, 2022
Biotechnology, Health, Oncology, Clinical Trials, COVID-19, Heparin, Private Securities Litigation Reform Act, Immune system, Radiation, IND, Syngenic, Twitter, U.S. Securities and Exchange Commission, NASDAQ, ARVO, Research, Eye, CO, VDC, Patient, Breast, Review, Association, Clinical trial, Neoplasm, Annual report, Cell, Colon, Acral lentiginous melanoma, Elisabete Weiderpass, LinkedIn, Intention, Kidney, SEC, Goal, Cancer, Annual general meeting, Risk, Choroid, Medical imaging, Pharmaceutical industry, Ophthalmology

AU-011 is in development for the treatment of multiple ocular oncology indications, including primary choroidal melanoma and choroidal metastasis.

Key Points: 
  • AU-011 is in development for the treatment of multiple ocular oncology indications, including primary choroidal melanoma and choroidal metastasis.
  • These results support our commitment to build our ocular oncology franchise and provide a potential novel treatment for patients with cancers in the eye.
  • We look forward to submitting the IND in choroidal metastases in the second half of this year.
  • Aura plans to develop AU-011 across its ocular oncology franchise including for the treatment of patients with choroidal metastases.

Results Published for Seraph 100 Treatment of COVID-19 Confirm Survival Benefit Signal

Retrieved on: 
Thursday, April 21, 2022
Medical Devices, Infectious Diseases, Health, Science, Research, Seraph, News, CEO, CE, Henry M. Jackson Foundation for the Advancement of Military Medicine, COVID-19, Mortality, Bacteria, RCT, Infection, DARPA, Hospital, Department, Patient, Fungus, Jean-Louis Vincent, Sepsis, ICU, Subclinical infection, Uniformed Services University of the Health Sciences, Trial of the century, Odds ratio, Military medicine, Vaccine, OBS, Heparin, Communication, Safety, EUA, Person, FDA, Pandemic, Virus, Survival, Pharmaceutical industry, MD, EU

The study includes analysis of 106 patients admitted to the ICU, 53 treated with Seraph 100 vs. 53 controls.

Key Points: 
  • The study includes analysis of 106 patients admitted to the ICU, 53 treated with Seraph 100 vs. 53 controls.
  • We are very pleased that, compared to contemporaneous controls, there was a strong signal of survival benefit for COVID-19 patients treated with the Seraph 100, said ExThera Medical Chairman and CEO Robert Ward.
  • We are encouraged that these results show that the Seraph 100 therapy is safe and well tolerated, said ExThera Medical Scientific Advisory Chair Lakhmir Chawla, MD.
  • These results justify multicenter randomized controlled trials to study the Seraph 100 in various critically ill patient populations suffering from sepsis.

Insights on the Buccal Drug Delivery Systems Global Market to 2028 - Featuring Pfizer, Catalent and Endo Pharmaceuticals Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, April 12, 2022
Health, Pharmaceutical, COVID-19, Research, Nicotine, Chapter Three, Analgesic, Morphine, Novadel-Agene, Insulin, COVID, Heparin, Smoking, Patient, Pharmaceutical industry

Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.

Key Points: 
  • Buccal drug delivery has gained large acceptance among geriatric patients and patients having difficulty swallowing.
  • Except for COVID medications, several other drug markets were majorly hit leading to the dip in the market for buccal drug delivery.
  • Buccal drug delivery is often the most preferred and effective formulation for treating patients with smoking or nicotine addiction
    Chapter 3.
  • Buccal drug delivery system Market Variables, Trends & Scope

ARCA biopharma Reports Topline Results for ASPEN-COVID-19 Phase 2b Clinical Trial

Retrieved on: 
Thursday, March 31, 2022
Company, DDU, ARCA, Population, WHO, Clinical trial, Heparin, IQR, Ddu-Du Ddu-Du, Safety, Intention, Nasdaq, ITT, COVID-19, GLOBE, Patient, Pharmaceutical industry

The clinical trial statistical analysis plan called for analysis of data stratified by a modified WHO COVID-19 Severity Scale that assigned randomized patients to either Mild or Severe groups.

Key Points: 
  • The clinical trial statistical analysis plan called for analysis of data stratified by a modified WHO COVID-19 Severity Scale that assigned randomized patients to either Mild or Severe groups.
  • We will continue to analyze the predefined clinical trial analyses, including important measurements such as antiphospholipid Abs.
  • At this time, ARCA is not planning further clinical development of rNAPc2 in COVID-19 in a direct superiority comparison to heparin design.
  • ARCA biopharma is dedicated to developing genetically and other targeted therapies for cardiovascular diseases through a precision medicine approach to drug development.

The Worldwide Heparin Industry is Expected to Reach $11.8 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Friday, March 25, 2022
Health, Pharmaceutical, CAGR, Market share analysis, USD, Strategic management, Investment, Customer support, Growth, Heparin, Certification, Use, Technology, COVID-19, Business Growth Fund, Value, R, Acquisition, Decision-making, Retail, Fine chemical

The Global Heparin Market size was estimated at USD 5,821.78 million in 2020 and expected to reach USD 6,419.68 million in 2021, at a CAGR of 10.70% to reach USD 11,862.15 million by 2027.

Key Points: 
  • The Global Heparin Market size was estimated at USD 5,821.78 million in 2020 and expected to reach USD 6,419.68 million in 2021, at a CAGR of 10.70% to reach USD 11,862.15 million by 2027.
  • It provides the idea of its revenue generation into the overall market compared to other vendors in the space.
  • Which are the products/segments/applications/areas to invest in over the forecast period in the Global Heparin Market?
  • What modes and strategic moves are considered suitable for entering the Global Heparin Market?

Aura Biosciences Announces Orphan Drug Designation Granted to AU-011 by European Commission for the Treatment of Uveal Melanoma (Includes Choroidal Melanoma)

Retrieved on: 
Monday, March 21, 2022
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, FDA, Clinical Trials, Private Securities Litigation Reform Act, Risk, LinkedIn, Radiation, Orphan, NASDAQ, Choroid, Regulatory affairs, Diagnosis, Uveal melanoma, European Commission, Ciliary body, SEC, Program, Medicine, Food, Acral lentiginous melanoma, VDC, Immune system, Royal commission, Review, Intention, Twitter, U.S. Securities and Exchange Commission, Goal, Iris, COVID-19, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Aura, Physician, EMA, Heparin, Union, Cell membrane, Patient, Pharmaceutical industry, EU, AU-011, AURA BIOSCIENCES, AU-011, AURA BIOSCIENCES

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma.

Key Points: 
  • Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that the European Commission has granted Orphan Drug Designation to AU-011, its first VDC product candidate, for the treatment of uveal melanoma.
  • The designation of uveal melanoma includes choroidal melanoma as well as melanomas of the iris and the ciliary body.
  • AU-011 was previously granted Orphan Drug Designation for the treatment of uveal melanoma by the U.S. Food and Drug Administration.
  • AU-011 is a first-in-class virus-like drug conjugate (VDC) therapy in clinical development for the first line treatment of choroidal melanoma.